Welcome! This blog contains research & information on lifestyle, nutrition and health for those with MS, as well as continuing information on the understanding of CCSVI and cerebral hypoperfusion. This blog is informative only--all medical decisions should be discussed with your own physicians.

The posts are searchable---simply type in your topic of interest in the search box at the top left.

Almost all of MS research is initiated and funded by pharmaceutical companies. This maintains the EAE mouse model and the immune paradigm of MS, and continues the 20 billion dollar a year MS treatment industry. But as we learn more about slowed blood flow, gray matter atrophy, and environmental links to MS progression and disability--all things the current drugs do not address--we're discovering more about how to help those with MS.

To learn how this journey began, read my first post from August, 2009. Be well! Joan

Wednesday, March 19, 2014

Chemotherapy causes brain atrophy, demyelination and MS disease progression

While many MS specialists continue to explore chemotherapies and immunoablation for people with MS, the side effects of these drugs on the brain are rarely mentioned.

As we learn more about the long term effects of chemotherapy of the central nervous system, it is vitally important that people with MS are given the facts.

If you are being recommended to try any of these therapies, please discuss the side effects with your doctor.

Recent studies have now started to unravel the cell‑biological basis for commonly seen neurotoxic syndromes in chemotherapy associated central nervous system damage and have provided compelling explanations for delayed neurological complications, such as cognitive decline, progressive myelin disruption and brain atrophy.
http://www.ncbi.nlm.nih.gov/pubmed/20738009

1. Chemotherapy kills myelin and OPC cells--  Chemotherapies are known to affect healthy brain cells, causing them to die off long after treatment ends.   Studies have shown that months after exposure to common chemotherapies, oligodendrocytes and precursor cells continue to die, and the brain is unable to remyelinate.

This study is the first model of a delayed degeneration syndrome that involves a global disruption of the myelin-forming cells that are essential for normal neuronal function,” said Mark Noble, Ph.D., director of the University of Rochester Stem Cell and Regenerative Medicine Institute and senior author of the study. “Because of our growing knowledge of stem cells and their biology, we can now begin to understand and define the molecular mechanisms behind the cognitive difficulties that linger and worsen in a significant number of cancer patients.”
http://www.urmc.rochester.edu/news/story/index.cfm?id=1963

2. Chemotherapy changes the brain's metabolism--  Doctors have long-described "chemo brain"--a common and debilitating side effect of chemotherapy, causing cognitive fog and a loss of coping skills.  In fact, the brain's metabolism is altered.

Chemo brain phenomenon is more than a feeling. It is not depression. It is a change in brain function observable on PET/CT brain imaging."
With the help of special software, they were able to pinpoint differences in brain metabolism before and after chemo. They then correlated these with patient history and data from neurologic exams and chemo treatments.  The analysis reveals a statistically significant link between reductions in regional brain metabolism and symptoms of chemo brain.  Lagos says their findings show "there are specific areas of the brain that use less energy following chemotherapy".

"These brain areas are the ones known to be responsible for planning and prioritizing," she adds.

http://www.medicalnewstoday.com/articles/253277.php

3. Chemotherapy used in bone marrow transplant doubles brain atrophy in those with progressive MS.    Because of this, one neurologist is now cautioning his progressive MS patients.  The chemotherapy used in bone marrow transplant is likely to accelerate the disease progression in those with progressive MS.

The following study I was involved shows that when SPMSers are given chemotherapy they undergo increased neuronal loss, which is associated with faster progression on the EDSS and greater brain atrophy. The data speaks for itself. The picture below is what we call a survival curve of EDSS progressions and you can see that the MSers who had high serum levels of the neuronal toxicity marker neurofilament were much more likely to progress than those who did not have raised neurofilament levels. Similarly, brain atrophy rates in SPMSers were in the order of 2.1% per year in those who had a BMT compared to only 1.2% per year in SPMSers who did not have a BMT; the upper limit of normal for brain atrophy in healthy adults is generally accepted to be 0.4% per year. The bottom line is that if you have SPMS BMT is likely to accelerate your disease progression.
http://multiple-sclerosis-research.blogspot.com/2014/02/more-on-bmt-neurotoxicity-and-brain.html

4. Current information on Lemtrada (Campath/Alemtuzumab)
New claims are that treatment reduced cerebral atrophy in RRMS patients who were followed for two years---but earlier studies showed that this was not true in secondary progressive MS.  Treated patients were followed for 14 years past infusions---and cerebral atrophy and disease progression continued.  The FDA was right to deny Lemtrada in the US---sadly, the MS patients that are asking for this treatment to be approved have been given an incomplete scenario.

Unfortunately, this did not lead to a clinical improvement in the disability in these patients. In fact, their disability worsened with time at a rate of 0.02 EDSS points for each patient each year. Evidence for continued neurodegeneration in these patients was shown by progressive cerebral atrophy on follow-up MRI scanning. This particular group of patients who showed continuing disease progression had the highest inflammatory load prior to commencing alemtuzumab therapy. This group of patients were followed up with MRI scanning many years later (14 years post treatment) and did not demonstrate any increase in lesion load but did demonstrate further cerebral atrophy [Coles et al. 2006]. This was reflected in their EDSS score, the median being 7.5 (range 4.5–9) at latest follow up [Hill-Cawthorne et al. 2012].
http://europepmc.org/articles/PMC3629751

Campath 1H treatment was associated with a sustained and marked reduction in the volume of Gd enhancement, indicating suppression of active inflammation. Nevertheless, many patients developed increasing brain and spinal cord atrophy, T1 hypointensity, and disability. 
http://www.ncbi.nlm.nih.gov/pubmed/10489036



In fact, neurologists have known about chemotherapy causing brain atrophy for many years.  Here is a study from 2006--where neurologists followed brain atrophy after chemotherapy in preparation for a bone marrow transplant.  And they included a man without MS, being treated for cancer, to see how his brain did.  His brain atrophy doubled....just like the people with MS.

The man with non-Hodgkin lymphoma provided a clue. Because he didn't have MS, he should not have had any cerebral inflammation or edema. Yet, in the three months after he received the same treatment as the MS patients, his brain shrank at the rate of about 6 percent per year, a rate of atrophy similar to the MS patients.
http://journals.lww.com/neurotodayonline/Fulltext/2006/07040/Brain_Atrophy_in_Ms_May_Result_From_Immunoablation.11.aspx

We still do not fully understand the disease mechanism of MS.  While MS specialists continue to operate under the assumption that a faulty immune system must be annihilated ----we are learning that the true progression of MS can be linked to neuronal loss, or brain atrophy.  There is a terrible and tragic irony in the fact that chemotherapies, which are known to double brain atrophy rates, are being recommended to people with MS.

Please, share this information in the MS community.  For those who have already been treated with chemotherapies, there is hope of healing through diets high in antioxidants and phytonutrients and omega 3 oil supplementation. In fact, simple lifestyle factors like diet, exercise, UV rays and vitamin D are increasing blood flow to the brain are helping reverse brain atrophy in all of those with MS.

Know the facts, and be well,
Joan


7 comments:

  1. il tutto si commenta da solo, nella speranza che la chemio sia dichiarata fuori legge !!

    ReplyDelete
  2. thank you for your post

    you could add Ocrelizumab and Ritixumab to your labels Joan, both being pushed on MS patients, there are reports of people on Crohns drug Remicade (Infliximab) developing MS type symptoms… Tysabri was originally called Natalizumab, Lemtrada was Alemtuzumab…

    remember you once wrote about Cladribrine, originally a chemotherapy drug used to treat leukaemias and lymphomas - introduced to the MS market in some countries and then withdrawn by Merck when even the FDA required more safety trials - not a whisper of the side effects and injuries caused to MS patients on it - it just vanishes - with certain immunologists still sad to see it go, such is their mindset that MS patients are somehow a disposable commodity


    Mitoxantrone, a chemotherapy drug used to treat acute myeloid leukaemia, non-Hodgkin lymphoma, advanced breast and advanced primary liver cancer has also been used in MS patients. Mitoxantrone is associated with accumulated cardiotoxicity and risks of leukaemia yet British neurologists still give it to MS patients despite warnings about it in the Lancet in 2003:

    'the suggestion that MS is an autoimmune disease associated with disease-specific dysregulation of T cells and B cells is unsubstantiated'

    http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)12875-9/fulltext#


    Neuroimmunologists worldwide are trying to recruit people onto trials of Ocrelizumab, a monoclonal antibody. Warnings about this have been given in the Lancet in 2012:

    http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60508- X/fulltext?rss=yes

    'The lessons from the clinical trial of natalizumab seem to have been forgotten too quickly: nearly a quarter of more than 200 patients with natalizumab-induced progressive multifocal leukoencephalopathy are dead and most of the rest are severely disabled by the drug rather then their disease. Quo vadis multiple sclerosis?'

    of course hundreds more have died from taking Tysabri (Natalizumab) since then as we know…


    imagine if there was a serial killer on the loose in North America with this many murders under his belt and the FBI did nothing to investigate and prosecute the perpetrator, yet 'science' and 'medicine' can seemingly kill or maim MS patients at will in pursuit of their cut of $15billion a year markets - the voices of the few doctors prepared to question this situation in public go unheeded

    and neurologists are certainly not disclosing this state of affairs to their patients, quite the opposite in fact - they are herding patients on to more and more chemotherapy and related clinical drug trials…. it is beyond me how this is considered ethical behaviour

    ReplyDelete
  3. Are there any recorded cases of chemotherapy causing MS as opposed to how chemotherapy affects people who already have MS?

    ReplyDelete
    Replies
    1. A search of the published literature does not show an MS diagnosis after chemotherapy, most likely because chemotherapy would be a known cause of problems in the CNS, and MS is a diagnosis of exclusion. Meaning, we typically do not understand what causes MS. And we understand what chemo can do....
      Chemotherapy has been known to cause demyelination and Lhermitte's sign (both also found in MS)
      http://www.ncbi.nlm.nih.gov/pubmed/24468536
      It causes white matter loss and demyelination (also seen in MS)
      http://www.nature.com/modpathol/journal/v17/n2/full/3800049a.html
      Chemotherapy affects the OPCs, the progenator cells which form myelin
      https://www.urmc.rochester.edu/biomedical-genetics/faculty/chemotherapy-induced-damage-to-cns.cfm

      All of these problems happened in people who did not have previous neurological disease. Chemo caused it. Hope that helps explain.

      Delete
  4. This is quite upsetting- especially as l go for HSCT in less than a month & in treating my MS this far was given cyclophosphamide intermittently with Betaseron by my ex neuro. What is one supposed to do w:this illness?!?! You go downhill eventually no matter what. I've been the good patient turned self advocating & educating patient. I've tried alternative therapies including CCSVI. I have an EDSS of 7 & am ASRRMD or SPMS at this point so wtf am l supposed to do with such info? Esp. as with other treatments l follow patient outcomes & l've several social media acquaintances doing great afterwards!! With any & all treatments there have been good and bad outcomes. So wish l hadn't seen this with the mountain l have to climb soon!!

    ReplyDelete
    Replies
    1. AARRMS sorry Siri doesn't always understand what I'm saying and then spellcheck didn't recognize this…

      Delete
  5. Sarah, everyone responds to treatment differently because of our Genetics/ Epigenetics. I carry several genes that are associated with MS and other chronic diseases. It did CCSVI and it helped. I exercised and that helped. I went back to school and got a PhD. I studied wellness. I learned Lifestyle changes support healthy genetic changes. Get your 23&me genetic test. Go to a physician-Integrative and Functional-who will advise you on how to support pathways that are slow functioning. You can repair your vascular and nervous tissues. Healing takes time, but we know enough to set you on the path to wellness. I eat a healthy diet, less animal protein, exercise daily, meditate,and take vitamins and antioxidants in forms that I can absorb and utilize. I no longer use a cane and I am mentally sharper than when I was 30. I am 61. Joan helped me see the path to wellness. Good luck on your journey.

    ReplyDelete